002737 葵花药业
交易中 06-22 13:53:12
资讯
新帖
简况
葵花药业(002737.SZ)子公司氟比洛芬凝胶贴膏获得药品注册证书
智通财经 · 06-15
葵花药业(002737.SZ)子公司氟比洛芬凝胶贴膏获得药品注册证书
葵花药业(002737.SZ)：盐酸氨溴索口服溶液申请注册上市许可获得受理
智通财经 · 06-04
葵花药业(002737.SZ)：盐酸氨溴索口服溶液申请注册上市许可获得受理
葵花药业严正声明
津云 · 06-02
葵花药业严正声明
葵花药业（002737）披露注销全资子公司进展公告，5月19日股价下跌0.08%
证券之星 · 05-19
葵花药业（002737）披露注销全资子公司进展公告，5月19日股价下跌0.08%
葵花药业：产品拟中选第四批全国中成药采购联盟集中带量采购
新京报 · 05-05
葵花药业：产品拟中选第四批全国中成药采购联盟集中带量采购
葵花药业(002737.SZ)发布一季度业绩，归母净利润1.1亿元，增长93.11%
智通财经 · 04-30
葵花药业(002737.SZ)发布一季度业绩，归母净利润1.1亿元，增长93.11%
葵花药业新提交“未公开”等2件商标注册申请
证券之星 · 04-18
葵花药业新提交“未公开”等2件商标注册申请
葵花药业（002737）披露投资设立湖北医药子公司进展公告，4月15日股价上涨2.37%
证券之星 · 04-15
葵花药业（002737）披露投资设立湖北医药子公司进展公告，4月15日股价上涨2.37%
葵花药业（002737）披露关于投资设立全资子公司的公告，4月3日股价下跌2.21%
证券之星 · 04-03
葵花药业（002737）披露关于投资设立全资子公司的公告，4月3日股价下跌2.21%
葵花药业(002737.SZ)拟1000万元投设湖北子公司
智通财经 · 03-31
葵花药业(002737.SZ)拟1000万元投设湖北子公司
葵花药业：公司将持续推进组织优化、模式升级、团队整风与文化回归
证券之星 · 03-17
葵花药业：公司将持续推进组织优化、模式升级、团队整风与文化回归
葵花药业（002737）披露变更签字注册会计师的公告，3月16日股价下跌1.1%
证券之星 · 03-16
葵花药业（002737）披露变更签字注册会计师的公告，3月16日股价下跌1.1%
葵花药业（002737）披露使用闲置自有资金进行现金管理进展公告，3月6日股价上涨1.27%
证券之星 · 03-06
葵花药业（002737）披露使用闲置自有资金进行现金管理进展公告，3月6日股价上涨1.27%
葵花药业最新公告：聘任王喜峰担任总经理（总裁）助理
证券之星 · 03-05
葵花药业最新公告：聘任王喜峰担任总经理（总裁）助理
葵花药业（002737）披露选举第五届董事会副董事长的公告，3月2日股价下跌2.07%
证券之星 · 03-02
葵花药业（002737）披露选举第五届董事会副董事长的公告，3月2日股价下跌2.07%
股市必读：葵花药业（002737）2月25日董秘有最新回复
证券之星 · 02-26
股市必读：葵花药业（002737）2月25日董秘有最新回复
葵花药业(002737.SZ)：复方聚乙二醇(3350)电解质口服溶液获药品注册证
智通财经 · 02-24
葵花药业(002737.SZ)：复方聚乙二醇(3350)电解质口服溶液获药品注册证
葵花药业创始人之女提前卸任总经理，“60后”职业经理人接棒，公司面临上市后首亏，关氏家族依旧掌控
红星资本局 · 02-10
葵花药业创始人之女提前卸任总经理，“60后”职业经理人接棒，公司面临上市后首亏，关氏家族依旧掌控
葵花药业：2月6日接受机构调研，中金银海(香港)基金有限公司、中润国信投资基金参与
证券之星 · 02-09
葵花药业：2月6日接受机构调研，中金银海(香港)基金有限公司、中润国信投资基金参与
股市必读：葵花药业（002737）2月2日董秘有最新回复
证券之星 · 02-03
股市必读：葵花药业（002737）2月2日董秘有最新回复
加载更多
公司概况
公司名称：
葵花药业集团股份有限公司
所属行业：
医药制造业
上市日期：
2014-12-30
主营业务：
葵花药业集团股份有限公司的主营业务是中成药、“化学药、生物药”和“健康养生品”的研发、制造与营销。公司的主要产品是中成药、化学药、营养保健品。公司荣获-第八届界面财经年会-“2025常春奖”-年度医药产业杰出企业，荣登中国健康产业（国际）生态大会（西普会）-“2025中国中成药企业综合竞争力50强”位列第17位。
发行价格：
36.53
{"stockData":{"symbol":"002737","market":"SZ","secType":"STK","nameCN":"葵花药业","latestPrice":11.87,"timestamp":1782107592000,"preClose":12.1,"halted":0,"volume":4226930,"delay":0,"changeRate":-0.019,"floatShares":584000000,"shares":584000000,"eps":-0.3505,"marketStatus":"交易中","change":-0.23,"latestTime":"06-22 13:53:12","open":12.1,"high":12.1,"low":11.61,"amount":49648000,"amplitude":0.0405,"askPrice":11.87,"askSize":37,"bidPrice":11.86,"bidSize":3,"shortable":0,"etf":0,"ttmEps":-0.3505,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1782111600000},"marketStatusCode":2,"adr":0,"adjPreClose":12.1,"symbolType":"stock","openAndCloseTimeList":[[1782091800000,1782099000000],[1782104400000,1782111600000]],"highLimit":13.31,"lowLimit":10.89,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":584000000,"isCdr":false,"pbRate":1.79,"roa":"--","roe":"2.83%","epsLYR":-0.44,"committee":-0.474333,"marketValue":6932000000,"turnoverRate":0.0072,"status":1,"floatMarketCap":6932000000},"requestUrl":"/m/hq/s/002737","defaultTab":"news","newsList":[{"id":"2643142279","title":"葵花药业(002737.SZ)子公司氟比洛芬凝胶贴膏获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2643142279","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643142279?lang=zh_cn&edition=full","pubTime":"2026-06-15 16:47","pubTimestamp":1781513259,"startTime":"0","endTime":"0","summary":"智通财经APP讯，葵花药业(002737.SZ)发布公告，公司控股子公司葵花药业集团(襄阳)隆中有限公司于近日收到国家药品监督管理局下发的氟比洛芬凝胶贴膏药品注册证书。据悉，氟比洛芬凝胶贴膏是一种非甾体抗炎药(NSAID)的外用制剂，核心优势在于通过经皮给药技术直接作用于患处，在局部血药浓度维持效果良好的同时，显著减少了口服给药带来的胃肠道副作用。米内网数据显示，氟比洛芬凝胶贴膏是中国外用制剂市场累计销售额突破100亿的品种，目前年销售额近40亿量级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454387.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","002737","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640130794","title":"葵花药业(002737.SZ)：盐酸氨溴索口服溶液申请注册上市许可获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2640130794","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640130794?lang=zh_cn&edition=full","pubTime":"2026-06-04 15:46","pubTimestamp":1780559171,"startTime":"0","endTime":"0","summary":"智通财经APP讯，葵花药业(002737.SZ)发布公告，公司全资子公司哈尔滨葵花药业有限公司于近日收到国家药品监督管理局下发的关于盐酸氨溴索口服溶液申请注册上市许可的《受理通知书》。拟定适应症(或功能主治)：用于急、慢性支气管炎引起的痰液粘稠、咳痰困难。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450071.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0028","IPOS","002737"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640791287","title":"葵花药业严正声明","url":"https://stock-news.laohu8.com/highlight/detail?id=2640791287","media":"津云","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640791287?lang=zh_cn&edition=full","pubTime":"2026-06-02 18:14","pubTimestamp":1780395240,"startTime":"0","endTime":"0","summary":"6月2日，葵花药业集团股份有限公司发布严正声明称，从未生产、销售或授权任何驱蚊类产品，驱蚊/防蚊类商品不在经营范围之内。报道及市场中出现的涉事“葵花”商标驱蚊产品，其商标注册主体为广东半分子健康产业有限公司。该公司与葵花药业不存在任何股权关联、隶属关系或商业合作，其开展的商标授权、产品生产及销售行为，均属独立商业行为，与葵花药业无关。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-06-02/doc-inhzzivp1597594.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","BK0028","002737"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636934832","title":"葵花药业（002737）披露注销全资子公司进展公告，5月19日股价下跌0.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636934832","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636934832?lang=zh_cn&edition=full","pubTime":"2026-05-19 17:48","pubTimestamp":1779184101,"startTime":"0","endTime":"0","summary":"截至2026年5月19日收盘，葵花药业报收于13.21元，较前一交易日下跌0.08%，最新总市值为77.15亿元。该股当日开盘13.25元，最高13.41元，最低13.19元，成交额达4371.24万元，换手率为0.56%。近日，葵花药业集团股份有限公司披露《关于注销全资子公司的进展公告》。本次注销事项不会对公司整体财务及经营情况产生重大影响，不存在损害公司及全体股东合法权益的情形。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900034114.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002737","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633129199","title":"葵花药业：产品拟中选第四批全国中成药采购联盟集中带量采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2633129199","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633129199?lang=zh_cn&edition=full","pubTime":"2026-05-05 18:52","pubTimestamp":1777978320,"startTime":"0","endTime":"0","summary":"新京报贝壳财经讯 葵花药业5月5日公告，全资子公司黑龙江葵花药业股份有限公司（简称“五常葵花”），参与了全国中成药联合采购办公室组织的第四批全国中成药采购联盟集中带量采购项目。根据4月30日发布的公示，五常葵花涉及的3个采购组产品护肝片、小儿肺热咳喘口服液/颗粒、健胃消食片在此次全国中成药集中带量采购项目中全部拟中选。","market":"hk","thumbnail":"https://media.bjnews.com.cn/cover/2026/05/05/5715794608877808809.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80","type":0,"news_type":0,"thumbnails":["https://media.bjnews.com.cn/cover/2026/05/05/5715794608877808809.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80"],"rights":{"source":"highlight_bjnews","url":"https://www.bjnews.com.cn/detail/1777975949129504.html","rn_cache_url":null,"customStyle":"handleCustomStyle(customStyle, ThemeStyle, getFont(fontSize))","selectors":"#main .nleft","filters":".ntit, .attitude","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bjnews.com.cn/detail/1777975949129504.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_bjnews","symbols":["BK0028","002737","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631549219","title":"葵花药业(002737.SZ)发布一季度业绩，归母净利润1.1亿元，增长93.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631549219","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631549219?lang=zh_cn&edition=full","pubTime":"2026-04-30 00:00","pubTimestamp":1777478422,"startTime":"0","endTime":"0","summary":"智通财经APP讯，葵花药业(002737.SZ)发布2026年第一季度报告，该公司营业收入为8.44亿元，同比增长27.19%。归属于上市公司股东的净利润为1.1亿元，同比增长93.11%。归属于上市公司股东的扣除非经常性损益的净利润为1.06亿元，同比增长166.22%。基本每股收益为0.19元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1436780.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"葵花药业(002737.SZ)发布一季度业绩，归母净利润1.1亿元，增长93.11%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002737"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628178063","title":"葵花药业新提交“未公开”等2件商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2628178063","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628178063?lang=zh_cn&edition=full","pubTime":"2026-04-18 06:50","pubTimestamp":1776466225,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示，近日葵花药业集团股份有限公司新提交“未公开”等2件商标注册申请。商标申请详情如下：今年以来葵花药业集团股份有限公司新申请注册商标2件，截止目前公司共持有注册商标62件，另有29件商标尚在注册申请中。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041800010240.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","002737"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627433407","title":"葵花药业（002737）披露投资设立湖北医药子公司进展公告，4月15日股价上涨2.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627433407","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627433407?lang=zh_cn&edition=full","pubTime":"2026-04-15 17:10","pubTimestamp":1776244204,"startTime":"0","endTime":"0","summary":"截至2026年4月15日收盘，葵花药业报收于12.51元，较前一交易日上涨2.37%，最新总市值为73.06亿元。该股当日开盘12.3元，最高12.63元，最低12.18元，成交额达8250.02万元，换手率为1.14%。葵花药业于2026年4月15日披露《关于投资设立葵花药业集团（湖北）医药有限公司的进展公告》。公告显示，公司于2026年3月31日召开第五届董事会第十九次会议，审议通过投资设立全资子公司的议案，使用自有资金1,000万元人民币设立葵花药业集团（湖北）医药有限公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041500030623.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1574","BK1515","BK0028","159938","09939","BK0239","002737"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624614654","title":"葵花药业（002737）披露关于投资设立全资子公司的公告，4月3日股价下跌2.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624614654","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624614654?lang=zh_cn&edition=full","pubTime":"2026-04-03 18:47","pubTimestamp":1775213230,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，葵花药业报收于12.4元，较前一交易日下跌2.21%，最新总市值为72.42亿元。该股当日开盘12.68元，最高12.75元，最低12.38元，成交额达4076.9万元，换手率为0.56%。近日，葵花药业集团股份有限公司发布《关于投资设立全资子公司的公告》。本次投资不涉及关联交易，不构成重大资产重组，无需提交股东会审议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300035991.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","002737"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623300383","title":"葵花药业(002737.SZ)拟1000万元投设湖北子公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2623300383","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623300383?lang=zh_cn&edition=full","pubTime":"2026-03-31 17:59","pubTimestamp":1774951198,"startTime":"0","endTime":"0","summary":"智通财经APP讯，葵花药业(002737.SZ)公告，公司决定使用自有资金1000万元投资设立全资子公司葵花药业集团(湖北)医药有限公司(筹)。本次投资设立全资子公司湖北医药公司，系公司基于“做精集团、做实子公司”战略规划，推动营销体系各模式、各业务板块独立核算、分线经营，强化资源精准配置、释放组织内生动力，提升公司整体运营效率。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423037.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002737","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620427838","title":"葵花药业：公司将持续推进组织优化、模式升级、团队整风与文化回归","url":"https://stock-news.laohu8.com/highlight/detail?id=2620427838","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620427838?lang=zh_cn&edition=full","pubTime":"2026-03-17 20:51","pubTimestamp":1773751882,"startTime":"0","endTime":"0","summary":"证券之星消息，葵花药业03月16日在投资者关系平台上答复投资者关心的问题。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031700039604.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002737","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619564664","title":"葵花药业（002737）披露变更签字注册会计师的公告，3月16日股价下跌1.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619564664","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619564664?lang=zh_cn&edition=full","pubTime":"2026-03-16 17:22","pubTimestamp":1773652925,"startTime":"0","endTime":"0","summary":"截至2026年3月16日收盘，葵花药业报收于12.55元，较前一交易日下跌1.1%，最新总市值为73.29亿元。近日，葵花药业集团股份有限公司发布公告称，因立信会计师事务所内部工作调整，委派张廷杰接替李星作为公司2025年度财务报告及内控报告审计项目的签字注册会计师。张廷杰自2026年起开始从事上市公司审计，近三年无刑事处罚、行政处罚、行政监管措施和自律处分记录，符合独立性要求。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600023953.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002737","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617063698","title":"葵花药业（002737）披露使用闲置自有资金进行现金管理进展公告，3月6日股价上涨1.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617063698","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617063698?lang=zh_cn&edition=full","pubTime":"2026-03-06 22:48","pubTimestamp":1772808492,"startTime":"0","endTime":"0","summary":"截至2026年3月6日收盘，葵花药业报收于13.6元，较前一交易日上涨1.27%，最新总市值为79.42亿元。该股当日开盘13.42元，最高13.62元，最低13.4元，成交额达2988.11万元，换手率为0.38%。近日，葵花药业集团股份有限公司发布《关于使用闲置自有资金进行现金管理的进展公告》。截至公告日，公司未到期现金管理余额为185,000万元。公司强调不影响生产经营，已采取风险控制措施。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030600040589.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","002737"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617514786","title":"葵花药业最新公告：聘任王喜峰担任总经理（总裁）助理","url":"https://stock-news.laohu8.com/highlight/detail?id=2617514786","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617514786?lang=zh_cn&edition=full","pubTime":"2026-03-05 16:32","pubTimestamp":1772699520,"startTime":"0","endTime":"0","summary":"葵花药业(002737.SZ)公告称，公司于2026年3月5日召开第五届董事会第十八次会议，审议通过聘任王喜峰担任公司总经理（总裁）助理，任期自董事会审议通过之日起至本届董事会届满之日止。王喜峰曾任公司总裁办副主任、主任等职务，现任公司董事长助理。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030500025984.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002737","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616803483","title":"葵花药业（002737）披露选举第五届董事会副董事长的公告，3月2日股价下跌2.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616803483","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616803483?lang=zh_cn&edition=full","pubTime":"2026-03-02 17:41","pubTimestamp":1772444492,"startTime":"0","endTime":"0","summary":"截至2026年3月2日收盘，葵花药业报收于13.74元，较前一交易日下跌2.07%，最新总市值为80.24亿元。该股当日开盘13.94元，最高14.06元，最低13.67元，成交额达5674.65万元，换手率为0.7%。近日，葵花药业集团股份有限公司披露《关于选举第五届董事会副董事长的公告》。公告显示，公司于2026年3月2日召开第五届董事会第十七次会议，审议通过选举关一女士为公司第五届董事会副董事长的议案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200026516.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002737","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614030852","title":"股市必读：葵花药业（002737）2月25日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2614030852","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614030852?lang=zh_cn&edition=full","pubTime":"2026-02-26 02:14","pubTimestamp":1772043253,"startTime":"0","endTime":"0","summary":"截至2026年2月25日收盘，葵花药业报收于14.09元，上涨0.43%，换手率0.37%，成交量2.14万手，成交额3013.84万元。来自公司公告汇总：子公司复方聚乙二醇电解质口服溶液获药品注册证书，适应症为慢性便秘、粪便嵌塞。该药品为化学药品3类，处方药，规格25ml/袋，适应症为治疗慢性便秘、粪便嵌塞。上市许可持有人为葵花药业集团（唐山）生物制药有限公司。审批结论为符合药品注册要求，批准注册，发给药品注册证书。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022600001232.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002737","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613603798","title":"葵花药业(002737.SZ)：复方聚乙二醇(3350)电解质口服溶液获药品注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2613603798","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613603798?lang=zh_cn&edition=full","pubTime":"2026-02-24 15:51","pubTimestamp":1771919478,"startTime":"0","endTime":"0","summary":"智通财经APP讯，葵花药业(002737.SZ)公告，公司子公司于近日收到国家药品监督管理局下发的关于复方聚乙二醇(3350)电解质口服溶液获批注册的药品注册证书。相关适应症为：治疗慢性便秘、粪便嵌塞。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406637.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"葵花药业(002737.SZ)：复方聚乙二醇(3350)电解质口服溶液获药品注册证","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0028","002737"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610640987","title":"葵花药业创始人之女提前卸任总经理，“60后”职业经理人接棒，公司面临上市后首亏，关氏家族依旧掌控","url":"https://stock-news.laohu8.com/highlight/detail?id=2610640987","media":"红星资本局","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610640987?lang=zh_cn&edition=full","pubTime":"2026-02-10 20:28","pubTimestamp":1770726480,"startTime":"0","endTime":"0","summary":" 葵花药业创始人之女提前卸任总经理，年薪484万，“60后”职业经理人接棒；公司面临上市后首亏，关氏家族依旧掌控。 2月9日晚，葵花药业宣布，公司创始人关彦斌之女关一，因个人原因辞去总经理职务，同时聘任周建忠为新任总经理。关一于2019年接任总经理一职，2020年，关彦斌因“杀妻案”获刑11年。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2026-02-10/doc-inhmixiy4384124.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["002737","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610509565","title":"葵花药业：2月6日接受机构调研，中金银海(香港)基金有限公司、中润国信投资基金参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2610509565","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610509565?lang=zh_cn&edition=full","pubTime":"2026-02-09 09:01","pubTimestamp":1770598860,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年2月8日葵花药业发布公告称公司于2026年2月6日接受机构调研，中金银海(香港)基金有限公司雍心 郭佳怡、中润国信投资基金崔建民参与。公司高管变动系正常人员流动，具体变动原因公司已在公告中进行披露。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020900001466.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002737","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608891743","title":"股市必读：葵花药业（002737）2月2日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2608891743","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608891743?lang=zh_cn&edition=full","pubTime":"2026-02-03 02:26","pubTimestamp":1770056771,"startTime":"0","endTime":"0","summary":"截至2026年2月2日收盘，葵花药业报收于13.98元，下跌0.71%，换手率0.67%，成交量3.9万手，成交额5491.07万元。公司公告汇总关于收到易活牌益生菌粉注册申请受理通知书的公告葵花药业集团股份有限公司全资子公司哈尔滨葵花药业有限公司近日收到国家市场监督管理总局下发的关于“易活牌益生菌粉”注册申请的《受理通知书》，受理号为国食健申G20260026，申请事项为国产保健食品新产品注册。经审查，决定予以受理。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020300001477.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","002737"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1782107597071,"stockEarnings":[{"period":"1week","weight":-0.0049},{"period":"1month","weight":-0.084},{"period":"3month","weight":-0.0242},{"period":"6month","weight":-0.2039},{"period":"1year","weight":-0.2038},{"period":"ytd","weight":-0.1808}],"compareEarnings":[{"period":"1week","weight":0.026},{"period":"1month","weight":-0.019},{"period":"3month","weight":0.0337},{"period":"6month","weight":0.0514},{"period":"1year","weight":0.2071},{"period":"ytd","weight":0.0306}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"葵花药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"47695人(较上一季度增加0.07%)","perCapita":"12244股","listingDate":"2014-12-30","address":"黑龙江省哈尔滨市道里区高新技术产业开发区迎宾路集中区东湖路18号","registeredCapital":"58400万元","survey":" 葵花药业集团股份有限公司的主营业务是中成药、“化学药、生物药”和“健康养生品”的研发、制造与营销。公司的主要产品是中成药、化学药、营养保健品。公司荣获-第八届界面财经年会-“2025常春奖”-年度医药产业杰出企业，荣登中国健康产业（国际）生态大会（西普会）-“2025中国中成药企业综合竞争力50强”位列第17位。","listedPrice":36.53},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"葵花药业(002737)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供葵花药业(002737)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"葵花药业,002737,葵花药业股票,葵花药业股票老虎,葵花药业股票老虎国际,葵花药业行情,葵花药业股票行情,葵花药业股价,葵花药业股市,葵花药业股票价格,葵花药业股票交易,葵花药业股票购买,葵花药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"葵花药业(002737)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供葵花药业(002737)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}